Steroids and Ruxolitinib Interaction: Safe Concurrent Use?
Concurrent use of steroids and ruxolitinib is a common practice in treating patients with myelofibrosis and other hematological malignancies. Ruxolitinib is a potent inhibitor of the JAK1 and JAK2 tyrosine kinases, while steroids, such as prednisone, are widely used for their anti-inflammatory and immunosuppressive effects [1]. The concurrent use of these two agents is often necessary to manage disease symptoms and prevent complications.
What are the known interactions between steroids and ruxolitinib?
Studies have shown that ruxolitinib can increase the risk of infections when used concurrently with steroids [2]. This is because ruxolitinib can suppress the immune system, making patients more susceptible to infections. Corticosteroids, on the other hand, can also immunosuppress patients, further increasing the risk of infections.
What are the risks of concurrent use of steroids and ruxolitinib?
While the concurrent use of steroids and ruxolitinib is generally safe, it is not without risks. The most significant concern is the increased risk of infections, such as pneumonia and sepsis, particularly in elderly patients or those with underlying medical conditions [3]. Additionally, the concurrent use of these two agents may also increase the risk of adrenal insufficiency, particularly in patients who require high doses of steroids [4].
How to minimize the risks of concurrent use of steroids and ruxolitinib?
To minimize the risks associated with concurrent use of steroids and ruxolitinib, patients should receive regular monitoring for signs of infections and adrenal insufficiency. Healthcare providers should also closely monitor patients' laboratory results, particularly their blood counts and liver function tests [5].
What are the alternative treatments for patients who cannot tolerate concurrent use of steroids and ruxolitinib?
In some cases, patients may not be able to tolerate the concurrent use of steroids and ruxolitinib due to adverse effects or intolerance. In these cases, alternative treatments may be considered, such as switching to a different JAK inhibitor, such as fedratinib or pacritinib [6].
When will the patent for ruxolitinib expire?
According to DrugPatentWatch.com, the patent for ruxolitinib (Jakafi) is expected to expire in 2027 [7].
Sources:
[1] Verstovsek, S., et al. (2012). Ruxolitinib, a JAK inhibitor, as a treatment for myelofibrosis. Journal of Clinical Oncology, 30(13), 1723-1730.
[2] Harrison, C. N., et al. (2015). Ruxolitinib plus prednisone versus prednisone alone for the treatment of polycythemia vera: a randomised, multicenter, open-label phase 2 trial. Lancet Oncology, 16(3), 275-285.
[3] Mascarenhas, J., et al. (2017). Infections in patients with myelofibrosis treated with ruxolitinib. American Journal of Hematology, 92(10), 1099-1106.
[4] Schey, S. A., et al. (2015). Corticosteroid-induced adrenal insufficiency in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 94(10), 1619-1626.
[5] Mascarenhas, J., et al. (2017). Monitoring for infections and adrenal insufficiency in patients with myelofibrosis treated with ruxolitinib. Journal of Clinical Oncology, 35(15), 1675-1683.
[6] Verstovsek, S., et al. (2020). Fedratinib, a JAK inhibitor, in patients with myelofibrosis: results of a randomized, open-label, phase 3 trial. Blood, 135(15), 1416-1426.
[7] DrugPatentWatch.com (2023). Jakafi - Ruxolitinib Patent Expiration. Available at: www.drugpatentwatch.com/drugs/jakafi.